vs
Side-by-side financial comparison of Cronos Group Inc. (CRON) and Regencell Bioscience Holdings Ltd (RGC). Click either name above to swap in a different company.
Cronos Group Inc. is a global cannabinoid firm specializing in cultivation, processing, and distribution of cannabis-derived products including wellness supplements, consumer goods, and medical cannabis. It serves North America, Europe, and Asia Pacific, catering to regulated recreational and medical consumer segments with quality-controlled offerings.
Regencell Bioscience Holdings Ltd is a specialized bioscience enterprise focused on the research, development and commercialization of therapeutic products derived from traditional Chinese medicine. Its core pipeline targets neurodegenerative, immunological and infectious disease treatments, with primary operating markets across Greater China and other Asian regions.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.5M | — | ||
| Q3 25 | $36.3M | — | ||
| Q2 25 | $33.5M | — | ||
| Q1 25 | $32.3M | — | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $34.3M | — | ||
| Q2 24 | $27.8M | — | ||
| Q1 24 | $25.3M | — |
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $26.0M | — | ||
| Q2 25 | $-39.7M | — | ||
| Q1 25 | $6.1M | — | ||
| Q4 24 | $43.7M | — | ||
| Q3 24 | $8.3M | — | ||
| Q2 24 | $-8.8M | — | ||
| Q1 24 | $-2.2M | — |
| Q4 25 | 36.4% | — | ||
| Q3 25 | 50.4% | — | ||
| Q2 25 | 43.4% | — | ||
| Q1 25 | 42.6% | — | ||
| Q4 24 | 35.7% | — | ||
| Q3 24 | 10.5% | — | ||
| Q2 24 | 22.7% | — | ||
| Q1 24 | 17.7% | — |
| Q4 25 | -16.8% | — | ||
| Q3 25 | -1.4% | — | ||
| Q2 25 | -15.9% | — | ||
| Q1 25 | -12.6% | — | ||
| Q4 24 | -37.5% | — | ||
| Q3 24 | -98.2% | — | ||
| Q2 24 | -56.1% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | -4.1% | — | ||
| Q3 25 | 71.4% | — | ||
| Q2 25 | -118.7% | — | ||
| Q1 25 | 19.0% | — | ||
| Q4 24 | 144.3% | — | ||
| Q3 24 | 24.4% | — | ||
| Q2 24 | -31.5% | — | ||
| Q1 24 | -8.9% | — |
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $0.07 | — | ||
| Q2 25 | $-0.10 | — | ||
| Q1 25 | $0.02 | — | ||
| Q4 24 | $0.12 | — | ||
| Q3 24 | $0.02 | — | ||
| Q2 24 | $-0.02 | — | ||
| Q1 24 | $-0.01 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
